{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T22:19:59Z","timestamp":1768515599700,"version":"3.49.0"},"posted":{"date-parts":[[2024,8,6]]},"group-title":"Bioengineering","reference-count":60,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Radionuclides used for imaging and therapy can show high molecular specificity in the body with appropriate targeting ligands. We hypothesized that local energy delivered by molecularly targeted radionuclides could chemically activate prodrugs at disease sites while avoiding activation in off-target sites of toxicity. As proof-of-principle, we tested whether this strategy of \u201c\n                  <jats:bold>RA<\/jats:bold>\n                  dionuclide\n                  <jats:bold>i<\/jats:bold>\n                  nduced\n                  <jats:bold>D<\/jats:bold>\n                  rug\n                  <jats:bold>E<\/jats:bold>\n                  ngagement for\n                  <jats:bold>R<\/jats:bold>\n                  elease\u201d (\n                  <jats:bold>RAiDER<\/jats:bold>\n                  ) could locally deliver combined radiation and chemotherapy to maximize tumor cytotoxicity while minimizing exposure to activated chemotherapy in off-target sites.\n                <\/jats:p>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>\n                    We screened the ability of radionuclides to chemically activate a model radiation-activated prodrug consisting of the microtubule destabilizing monomethyl auristatin E caged by a radiation-responsive phenyl azide (\u201ccaged-MMAE\u201d) and interpreted experimental results using the radiobiology computational simulation suite TOPAS-nBio. RAiDER was evaluated in syngeneic mouse models of cancer using fibroblast activation protein inhibitor (FAPI) agents\n                    <jats:sup>99m<\/jats:sup>\n                    Tc-FAPI-34 and\n                    <jats:sup>177<\/jats:sup>\n                    Lu-FAPI-04, the prostate-specific membrane antigen (PSMA) agent\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA-617, combined with caged-MMAE or caged-exatecan. Biodistribution in mice, combined with clinical dosimetry, estimated the relationship between radiopharmaceutical uptake in patients and anticipated concentrations of activated prodrug using RAiDER.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\n                    RAiDER efficiency varied by 250-fold across radionuclides (\n                    <jats:sup>99m<\/jats:sup>\n                    Tc&gt;\n                    <jats:sup>177<\/jats:sup>\n                    Lu&gt;\n                    <jats:sup>64<\/jats:sup>\n                    Cu&gt;\n                    <jats:sup>68<\/jats:sup>\n                    Ga&gt;\n                    <jats:sup>223<\/jats:sup>\n                    Ra&gt;\n                    <jats:sup>18<\/jats:sup>\n                    F), yielding up to 1.22\u00b5M prodrug activation per Gy of exposure from\n                    <jats:sup>99m<\/jats:sup>\n                    Tc. Computational simulations implicated low-energy electron-mediated free radical formation as driving prodrug activation. Clinically relevant radionuclide concentrations chemically activated caged-MMAE restored its ability to destabilize microtubules and increased its cytotoxicity by up to 600-fold compared to non-irradiated prodrug. Mice treated with\n                    <jats:sup>99m<\/jats:sup>\n                    Tc-FAPI-34 and caged-MMAE accumulated up to 3000\u00d7 greater concentrations of activated MMAE in tumors compared to other tissues. RAiDER with\n                    <jats:sup>99m<\/jats:sup>\n                    Tc-FAPI-34 or\n                    <jats:sup>177<\/jats:sup>\n                    Lu-FAPI-04 delayed tumor growth, while monotherapies did not (\n                    <jats:italic>P<\/jats:italic>\n                    &lt;0.03). Clinically-guided dosimetry suggests sufficient radiation doses can be delivered to activate therapeutically meaningful levels of prodrug.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This proof-of-concept study shows that RAiDER is compatible with multiple radionuclides commonly used in nuclear medicine and has the potential to improve the efficacy of radiopharmaceutical therapies to treat cancer safely. RAiDER thus shows promise as an effective strategy to treat disseminated malignancies and broadens the capability of radiopharmaceuticals to trigger diverse biological and therapeutic responses.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Abstract Figure<\/jats:title>\n                  <jats:fig id=\"ufig1\" position=\"float\" orientation=\"portrait\" fig-type=\"figure\">\n                    <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"606075v1_ufig1\" position=\"float\" orientation=\"portrait\"\/>\n                  <\/jats:fig>\n                <\/jats:sec>","DOI":"10.1101\/2024.08.02.606075","type":"posted-content","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T21:01:32Z","timestamp":1722978092000},"source":"Crossref","is-referenced-by-count":0,"title":["Localized\n                  <i>in vivo<\/i>\n                  prodrug activation using radionuclides"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9820-1297","authenticated-orcid":false,"given":"J.M.","family":"Quintana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3679-4012","authenticated-orcid":false,"given":"F.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Valladolid Onecha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9397-8600","authenticated-orcid":false,"given":"A.","family":"K\u00f6nik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.E.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2866-9358","authenticated-orcid":false,"given":"H.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Borges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9290-5856","authenticated-orcid":false,"given":"L.I.","family":"Banla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8680-0903","authenticated-orcid":false,"given":"M.","family":"Le Fur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3179-6537","authenticated-orcid":false,"given":"P.","family":"Caravan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7554-8818","authenticated-orcid":false,"given":"J.","family":"Schuemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9890-693X","authenticated-orcid":false,"given":"A.","family":"Bertolet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0828-4143","authenticated-orcid":false,"given":"R.","family":"Weissleder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7638-8898","authenticated-orcid":false,"given":"M.A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3676-1800","authenticated-orcid":false,"given":"T.S.C.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024080812251199000_2024.08.02.606075v1.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2024080812251199000_2024.08.02.606075v1.2","doi-asserted-by":"crossref","unstructured":"Strosberg JR , Wolin EM , Chasen B , et al. NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-dotatate. American Society of Clinical Oncology; 2016.","DOI":"10.1200\/jco.2016.34.4_suppl.194"},{"key":"2024080812251199000_2024.08.02.606075v1.3","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics in oncology: current challenges and emerging opportunities","volume":"19","year":"2022","journal-title":"Nature Reviews Clinical Oncology"},{"key":"2024080812251199000_2024.08.02.606075v1.4","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/S1470-2045(19)30821-6","article-title":"Radiotheranostics: a roadmap for future development","volume":"21","year":"2020","journal-title":"The Lancet Oncology"},{"key":"2024080812251199000_2024.08.02.606075v1.5","doi-asserted-by":"crossref","first-page":"17588359231187202","DOI":"10.1177\/17588359231187202","article-title":"Novel radionuclide therapy combinations in prostate cancer","volume":"15","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"2024080812251199000_2024.08.02.606075v1.6","doi-asserted-by":"crossref","unstructured":"Adant S , Shah GM , Beauregard J-M . Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging. 2019.","DOI":"10.1007\/s00259-019-04499-x"},{"key":"2024080812251199000_2024.08.02.606075v1.7","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.cell.2023.02.039","article-title":"Advances in cancer immunotherapies","volume":"186","year":"2023","journal-title":"Cell"},{"key":"2024080812251199000_2024.08.02.606075v1.8","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3390\/cancers14030627","article-title":"Chemotherapy side-effects: not all DNA damage is equal","volume":"14","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2024080812251199000_2024.08.02.606075v1.9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/1740774520975120","article-title":"Composite grading algorithm for the National cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"18","year":"2021","journal-title":"Clinical Trials"},{"key":"2024080812251199000_2024.08.02.606075v1.10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00262-021-03013-3","article-title":"Chemotherapy: a double-edged sword in cancer treatment","volume":"71","year":"2022","journal-title":"Cancer immunology, immunotherapy"},{"key":"2024080812251199000_2024.08.02.606075v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2011.02.002"},{"key":"2024080812251199000_2024.08.02.606075v1.12","doi-asserted-by":"crossref","first-page":"12814","DOI":"10.1021\/acsnano.8b07954","article-title":"Modular Nanoparticulate Prodrug Design Enables Efficient Treatment of Solid Tumors Using Bioorthogonal Activation","volume":"12","year":"2018","journal-title":"ACS Nano"},{"key":"2024080812251199000_2024.08.02.606075v1.13","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1021\/acscentsci.3c00286","article-title":"New Pathway for Cisplatin Prodrug to Utilize Metabolic Substrate Preference to Overcome Cancer Intrinsic Resistance","volume":"9","year":"2023","journal-title":"ACS Central Science"},{"key":"2024080812251199000_2024.08.02.606075v1.14","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1021\/acs.bioconjchem.1c00131","article-title":"Hypoxia-activated prodrug enabling synchronous chemotherapy and HIF-1\u03b1 downregulation for tumor treatment","volume":"32","year":"2021","journal-title":"Bioconjugate chemistry"},{"key":"2024080812251199000_2024.08.02.606075v1.15","doi-asserted-by":"crossref","first-page":"15906","DOI":"10.1038\/ncomms15906","article-title":"Nano-palladium is a cellular catalyst for in vivo chemistry","volume":"8","year":"2017","journal-title":"Nature CommunicaIons"},{"key":"2024080812251199000_2024.08.02.606075v1.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41563-020-0755-z"},{"key":"2024080812251199000_2024.08.02.606075v1.17","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0520-6"},{"key":"2024080812251199000_2024.08.02.606075v1.18","doi-asserted-by":"crossref","unstructured":"Nguyen TD , Bordeau BM , Balthasar JP . Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. Cancers (Basel ). 2023;15.","DOI":"10.3390\/cancers15030713"},{"key":"2024080812251199000_2024.08.02.606075v1.19","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1021\/acs.bioconjchem.2c00174","article-title":"Radiation Cleaved Drug-Conjugate Linkers Enable Local Payload Release","volume":"33","year":"2022","journal-title":"Bioconjugate Chemistry"},{"key":"2024080812251199000_2024.08.02.606075v1.20","doi-asserted-by":"crossref","unstructured":"Kang M , Quintana J , Hu H , et al. Sustained and Localized Drug Depot Release using Radiation-Activated Scintillating Nanoparticles. Advanced Materials. 2024:2312326.","DOI":"10.1002\/adma.202312326"},{"key":"2024080812251199000_2024.08.02.606075v1.21","doi-asserted-by":"crossref","unstructured":"Fu Q , Gu Z , Shen S , et al. Radiotherapy activates picolinium prodrugs in tumours. Nat Chem. 2024.","DOI":"10.1038\/s41557-024-01501-4"},{"key":"2024080812251199000_2024.08.02.606075v1.22","doi-asserted-by":"crossref","unstructured":"Xu Z , Zhen W , McCleary C , et al. Nanoscale Metal\u2013Organic Framework with an X-ray Triggerable Prodrug for Synergistic Radiotherapy and Chemotherapy. J Am Chem Soc. 2023.","DOI":"10.1021\/jacs.3c04602"},{"key":"2024080812251199000_2024.08.02.606075v1.23","doi-asserted-by":"crossref","unstructured":"Quintana JM , Kang M , Hu H , et al. Extended Pharmacokinetics Improve Site-Specific Prodrug Activation Using Radiation. ACS Central Science. 2024.","DOI":"10.1021\/acscentsci.4c00354"},{"key":"2024080812251199000_2024.08.02.606075v1.24","first-page":"497","article-title":"The Emerging Role of Radiotherapy in Oligoprogressive Non-Small Cell Lung Cancer","volume":"32","year":"2023","journal-title":"Surgical Oncology Clinics"},{"key":"2024080812251199000_2024.08.02.606075v1.25","doi-asserted-by":"publisher","DOI":"10.1021\/bc000145v"},{"key":"2024080812251199000_2024.08.02.606075v1.26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00253164","article-title":"Stabilization of 99m Tc-pyrophosphate injection with gentisic acid","volume":"6","year":"1981","journal-title":"Eur J Nucl Med"},{"key":"2024080812251199000_2024.08.02.606075v1.27","doi-asserted-by":"crossref","unstructured":"Wang C , Xu M , Zhang Z , et al. Locally unlocks prodrugs by radiopharmaceutical in tumor for cancer therapy. Science BulleIn. 2024.","DOI":"10.1016\/j.scib.2024.07.010"},{"key":"2024080812251199000_2024.08.02.606075v1.28","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1021\/acs.bioconjchem.7b00665","article-title":"Mechanistic Evaluation of Bioorthogonal Decaging with trans- Cyclooctene: The Effect of Fluorine Substituents on Aryl Azide Reactivity and Decaging from the 1,2,3- Triazoline","volume":"29","year":"2018","journal-title":"Bioconjug Chem"},{"key":"2024080812251199000_2024.08.02.606075v1.29","doi-asserted-by":"crossref","unstructured":"Ng TSC , Gunda V , Li R , et al. Detecting Immune Response to Therapies Targeting PDL1 and BRAF by Using Ferumoxytol MRI and Macrin in Anaplastic Thyroid Cancer. Radiology. 2020:201791.","DOI":"10.1148\/radiol.2020201791"},{"key":"2024080812251199000_2024.08.02.606075v1.30","doi-asserted-by":"crossref","unstructured":"Li R , Ng TSC , Wang SJ , et al. Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer. Nature Nanotechnology. 2021.","DOI":"10.1038\/s41565-021-00897-1"},{"key":"2024080812251199000_2024.08.02.606075v1.31","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0818"},{"key":"2024080812251199000_2024.08.02.606075v1.32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12645-019-0047-y","article-title":"Importance of radiolytic reactions during high-LET irradiation modalities: LET effect, role of O2 and radiosensitization by nanoparticles","volume":"10","year":"2019","journal-title":"Cancer Nanotechnol"},{"key":"2024080812251199000_2024.08.02.606075v1.33","first-page":"1384","article-title":"Prevention of radiolysis of monoclonal antibody during labeling","volume":"37","year":"1996","journal-title":"J Nucl Med."},{"key":"2024080812251199000_2024.08.02.606075v1.34","doi-asserted-by":"crossref","first-page":"105014","DOI":"10.1088\/1361-6560\/aac04c","article-title":"Monte Carlo simulation of chemistry following radiolysis with TOPAS-nBio","volume":"63","year":"2018","journal-title":"Phys Med Biol"},{"key":"2024080812251199000_2024.08.02.606075v1.35","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/jrr\/rrac105","article-title":"Application of Geant4-DNA for simulating water radiolysis induced by Auger electron-emiqng radionuclides","volume":"64","year":"2023","journal-title":"Journal of RadiaIon Research"},{"key":"2024080812251199000_2024.08.02.606075v1.36","doi-asserted-by":"crossref","first-page":"19282","DOI":"10.1039\/c3ra42984a","article-title":"Self-radiolysis of tritiated water. 1. A comparison of the effects of 60Co \u03b3-rays and tritium \u03b2-particles on water and aqueous solutions at room temperature","volume":"3","year":"2013","journal-title":"RSC Advances"},{"key":"2024080812251199000_2024.08.02.606075v1.37","doi-asserted-by":"crossref","first-page":"102540","DOI":"10.1016\/j.ejmp.2023.102540","article-title":"Effects of incoming particle energy and cluster size on the G-value of hydrated electrons","volume":"107","year":"2023","journal-title":"Phys Med"},{"key":"2024080812251199000_2024.08.02.606075v1.38","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/3579851","article-title":"Effect of electron energy on the radiation chemistry of liquid water","volume":"150","year":"1998","journal-title":"Radiat Res"},{"key":"2024080812251199000_2024.08.02.606075v1.39","doi-asserted-by":"crossref","first-page":"e14301","DOI":"10.1002\/acm2.14301","article-title":"SpekPy Web\u2014online x-ray spectrum calculations using an interface to the SpekPy toolkit","volume":"25","year":"2024","journal-title":"J Appl Clin Med Phys"},{"key":"2024080812251199000_2024.08.02.606075v1.40","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.rpor.2012.12.001","article-title":"Effect of anode angle on photon beam spectra and depth dose characteristics for X-RAD320 orthovoltage unit","volume":"18","year":"2013","journal-title":"Reports of PracIcal Oncology & Radiotherapy"},{"key":"2024080812251199000_2024.08.02.606075v1.41","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s13139-019-00587-w","article-title":"Development of a Novel Imaging Agent for Determining Albumin Uptake in Solid Tumors","volume":"53","year":"2019","journal-title":"Nucl Med Mol Imaging"},{"key":"2024080812251199000_2024.08.02.606075v1.42","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.2967\/jnumed.119.239731","article-title":"Design and Development of (99m)Tc-Labeled FAPI Tracers for SPECT Imaging and (188)Re Therapy","volume":"61","year":"2020","journal-title":"J Nucl Med"},{"key":"2024080812251199000_2024.08.02.606075v1.43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2191-219X-4-14","article-title":"Optimising the radiolabelling properties of technetium tricarbonyl and His-tagged proteins","volume":"4","year":"2014","journal-title":"EJNMMI Res"},{"key":"2024080812251199000_2024.08.02.606075v1.44","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.170423"},{"key":"2024080812251199000_2024.08.02.606075v1.45","doi-asserted-by":"crossref","unstructured":"Ruigrok EAM , van Vliet N , Dalm SU , et al. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2020.","DOI":"10.1007\/s00259-020-05057-6"},{"key":"2024080812251199000_2024.08.02.606075v1.46","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.233122"},{"key":"2024080812251199000_2024.08.02.606075v1.47","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"},{"key":"2024080812251199000_2024.08.02.606075v1.48","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13550-022-00947-2","article-title":"Relationships between uptake of [(68)Ga]Ga-DOTA-TATE and absorbed dose in [(177)Lu]Lu-DOTA-TATE therapy","volume":"12","year":"2022","journal-title":"EJNMMI Res"},{"key":"2024080812251199000_2024.08.02.606075v1.49","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264225"},{"key":"2024080812251199000_2024.08.02.606075v1.50","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.126177"},{"key":"2024080812251199000_2024.08.02.606075v1.51","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262713"},{"key":"2024080812251199000_2024.08.02.606075v1.52","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1007\/s00259-022-06068-1","article-title":"The role of [99mTc]Tc-HFAPi SPECT\/CT in patients with malignancies of digestive system: first clinical experience","volume":"50","year":"2023","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"2024080812251199000_2024.08.02.606075v1.53","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1158\/1078-0432.CCR-22-2976","article-title":"Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin\u2013Drug Conjugate Response","volume":"29","year":"2023","journal-title":"Clinical Cancer Research"},{"key":"2024080812251199000_2024.08.02.606075v1.54","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41586-024-07461-6","article-title":"Covalent targeted radioligands potentiate radionuclide therapy","volume":"630","year":"2024","journal-title":"Nature"},{"key":"2024080812251199000_2024.08.02.606075v1.55","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1021\/acscentsci.3c00288","article-title":"Covalent Proteins as Targeted Radionuclide Therapies Enhance Antitumor Effects","volume":"9","year":"2023","journal-title":"ACS Central Science"},{"key":"2024080812251199000_2024.08.02.606075v1.56","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1039\/f19817702803","article-title":"Effect of radiation type in water radiolysis","volume":"77","year":"1981","journal-title":"Journal of the Chemical Society, Faraday TransacIons 1: Physical Chemistry in Condensed Phases"},{"key":"2024080812251199000_2024.08.02.606075v1.57","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-2295"},{"key":"2024080812251199000_2024.08.02.606075v1.58","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1158\/1535-7163.MCT-22-0375","article-title":"Antibody\u2013Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release","volume":"22","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"2024080812251199000_2024.08.02.606075v1.59","doi-asserted-by":"crossref","unstructured":"Ng TSC , Hu H , Kronister S , et al. Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy. Science Advances.8:eabl6339.","DOI":"10.1126\/sciadv.abl6339"},{"key":"2024080812251199000_2024.08.02.606075v1.60","doi-asserted-by":"crossref","first-page":"1331364","DOI":"10.3389\/fnume.2024.1331364","article-title":"Immunological effects of radiopharmaceutical therapy","volume":"4","year":"2024","journal-title":"FronIers in Nuclear Medicine"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.08.02.606075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:49:21Z","timestamp":1768459761000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2024.08.02.606075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":60,"URL":"https:\/\/doi.org\/10.1101\/2024.08.02.606075","relation":{},"subject":[],"published":{"date-parts":[[2024,8,6]]},"subtype":"preprint"}}